论文部分内容阅读
2013年10月25日,美国食品药品监督管理局(FDA)批准由GE Healthcare Ltd的分公司Medi-Physics生产的放射性诊断药物[18F]flutemetamol注射液(Vizamyl)在美国上市。[18F]flutemetamol是一种F18标记的硫磺素T类似物,能够被阿尔茨海默病(AD)患者大脑摄取、滞留,通过PET扫描显示淀粉样蛋白斑。主要用于成人患者阿尔茨海默病(AD)和痴呆症评价时的脑部正电子发射断层扫描(PET)成像[1]。[18F]flutemetamol中文化学名称:2-[3-(18氟)-4-
On October 25, 2013, the U.S. Food and Drug Administration (FDA) approved the listing of the radiodiagnostic drug [18F] flutemetamol injection (Vizamyl) manufactured by Medi-Physics, a division of GE Healthcare Ltd., in the United States. [18F] flutemetamol is a F18-labeled Thioflavin T analogue that can be taken up and retained in the brain of patients with Alzheimer's disease (AD) and shows amyloid plaques on PET scans. Mainly used in adult patients with Alzheimer's disease (AD) and dementia brain evaluation of positron emission tomography (PET) imaging [1]. [18F] flutemetamol Chinese chemical name: 2- [3- (18-fluoro) -4-